XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Fair Value of Options
The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Expected stock price volatility58.4 %61.0 %59.2 %62.2 %
Risk free interest rate4.3 %3.1 %3.9 %1.7 %
Expected life of options (years)5.55.35.55.3
Expected annual dividend per share$— $— $— $— 
Schedule of Stock Options Activity A summary of the Company's stock options for the nine months ended September 30, 2023 were as follows:
Number of
Shares
Weighted Average Exercise 
Price
Weighted Average Remaining
Years
Aggregate
Intrinsic
Value
 (in thousands)  (in millions)
Options outstanding, December 31, 202219,064 $11.31   
Granted5,522 $12.03   
Exercised(1,032)$7.61   
Forfeited(248)$11.51   
Expired(50)$14.39 
Options outstanding, September 30, 202323,256 $11.64 6.7$32.1 
Vested and unvested expected to vest, September 30, 202321,389 $11.58 6.5$31.1 
Exercisable at September 30, 202313,246 $11.12 5.1$27.9 
Schedule of Non-Vested RSU Activity under the Plan A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2023 is as follows:
Number of
Shares
Weighted
Average Grant
Date Fair
Value
Weighted 
Average
Remaining 
Years
Aggregate
Intrinsic
Value
(in thousands)(in millions)
Non-vested units as of December 31, 20229,717 $13.07   
Granted4,514 $13.08   
Vested(3,252)$12.25   
Forfeited(648)$10.07   
Non-vested units as of September 30, 202310,331 $13.56 2.2$125.6 
Schedule of Equity Compensation Expenses
The following table summarizes information related to compensation expense recognized in the Company's Consolidated Statements of Operations related to the equity awards:
 Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)2023202220232022
Research and development expense$4,380 $5,428 $16,987 $19,172 
Selling, general, and administrative expense12,131 9,344 50,995 38,714 
Total equity compensation expense$16,511 $14,772 $67,982 $57,886